management system have achieved some Final recommendations on the composition of the influenza vaccine for the next campaign (2024-2025), This follows several days of meetings with an expert advisory group from WHO collaborating centers and its key regulatory laboratories.
National vaccine regulators and pharmaceutical companies will need to introduce these changes for the development, production and licensing of upcoming vaccines. The World Health Organization assures that because the virus is constantly changing and evolving, regular updates are necessary to ensure effectiveness.
There are three main recommendations regarding different versions of the vaccine:
– this Egg trivalent vaccine Viruses used in the Northern Hemisphere 2022-2023 influenza season contain viruses similar to A/Victoria/4897/2022 (H1N1)pdm09; viruses similar to A/Thailand/8/2022 (H3N2); and viruses similar to B/Austria/1359417/2021 (B/Victoria lineage) similar viruses.
– Cell culture or recombinant vaccines It is suggested that they contain viruses similar to A/Wisconsin/67/2022 (H1N1)pdm09; viruses similar to A/Massachusetts/18/2022 (H3N2); and viruses similar to B/Austria/1359417/2021 (B/Victoria lineage) of viruses.
– Quadrivalent vaccines based on ovules or cell cultures or recombinants For use in the 2024-2025 northern hemisphere influenza season, WHO recommends that viruses similar to B/Phuket/3073/2013 (B/Yamagata lineage) be included as part of the B/Yamagata lineage.